| Li, Xin |
| Active, not recruiting | 4 | 948 | Europe, Canada, US, RoW | Edoxaban, Lixiana, Savaysa, Non-anticoagulant medical therapy | Population Health Research Institute | Intracranial Hemorrhages, Atrial Fibrillation | 04/26 | 10/26 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT04025164: Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery |
|
|
| Recruiting | 3 | 4052 | RoW | Hypofractionated Radiotherapy, Experimental Arm, Conventional fractionated Radiotherapy, Standard Arm | Fudan University | Breast Cancer | 06/23 | 06/28 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
NCT06601504: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 60 | RoW | HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2 | Hutchmed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 05/26 | 11/26 | | |
NCT05768529: Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1/2 | 100 | RoW | U16 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Relapsed or Refractory Non-Hodgkin's Lymphoma | 12/24 | 12/26 | | |
NCT04673799: Comparing of the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults. |
|
|
| Not yet recruiting | 1 | 144 | NA | MV088 injection, Prolia® injection | Kunming Pharmaceuticals, Inc. | Healthy | 10/21 | 10/21 | | |
| Completed | 1 | 100 | RoW | AK104 (before the change), AK104 (after the change) | Akeso | Healthy Male Subjects | 03/23 | 04/23 | | |
NCT05758428: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects |
|
|
| Completed | 1 | 28 | RoW | Ensifentrine, Placebo | Nuance Pharma (shanghai) Co., Ltd | Chronic Obstructive Pulmonary Disease | 04/23 | 04/23 | | |
GNC-035-103, NCT05160545: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 1 | 29 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 06/25 | 12/25 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
NCT05505812: Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer |
|
|
| Not yet recruiting | 1 | 10 | RoW | HS-IT101 | The Affiliated Hospital of Qingdao University, Qingdao Sino-Cell Biomedicine Co.,Ltd. | Breast Cancer | 12/23 | 03/27 | | |
| Not yet recruiting | 1 | 12 | RoW | NTQ5082 capsule | Nanjing Chia-tai Tianqing Pharmaceutical | Complement-mediated Hemolytic Diseases | 12/24 | 02/25 | | |
NCT06560593: A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 82 | RoW | NTQ5082, Placebo | Nanjing Chia-tai Tianqing Pharmaceutical | Complement-mediated Hemolytic Diseases | 12/24 | 02/25 | | |
NCT06196060: Improving ToM in Children With ASD Through VPT Training: Behavioral and fNIRS Study |
|
|
| Recruiting | N/A | 100 | RoW | Visual perspective taking training, Block building training, Thought-bubble training, Treatment as usual | Nanjing Normal University, Zhuhai Fudan Innovation Institute, Second Affiliated Hospital of Guangxi Medical University | Autism Spectrum Disorder | 06/24 | 09/24 | | |
NCT06579976: Multimodal High-frequency Ultrasound-based Study of Plaque Psoriasis Severity Index |
|
|
| Not yet recruiting | N/A | 45 | RoW | No intervention | Shanghai Yueyang Integrated Medicine Hospital | Plaque Psoriasis | 02/25 | 05/25 | | |
NCT05665010: Precise Stratification of Genetic Risk of Ovarian Function Impairment |
|
|
| Recruiting | N/A | 1000 | RoW | Genetic susceptibility | Tongji Hospital | Premature Ovarian Insufficiency, Diminished Ovarian Reserve, Early Menopause | 10/23 | 10/24 | | |
| Xue, Hongwei |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT05498636: SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression |
|
|
| Not yet recruiting | 1/2 | 67 | RoW | Selinexor combined with Prednisone, Etoposide, and Lenalidomide | The Affiliated Hospital of Qingdao University | DLBCL | 07/25 | 12/25 | | |
| Gao, YiJu |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
